Recent Finacing
Recent Raise
Ancilia Biosciences develops CRISPR-based virus-resistant live bacterial products for human health and other applications, using CoVE to identify/characterize phages and EPIC to engineer CRISPR-mediated viral immunity.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Ancilia Biosciences.
